$238.970
-3.226 (-1.35%)At close
RMD News
RMD Events
Resmed Completes Sale of MatrixCare to Frazier Healthcare
Resmed announced the closing of its sale of MatrixCare to Frazier Healthcare Partners, a private equity firm focused on the healthcare industry. MatrixCare is a provider of cloud-based electronic health record and revenue cycle management solutions purpose-built for out-of-hospital care settings, including skilled nursing, senior living, home health, hospice, and life plan communities. MatrixCare is used by thousands of facility-based and home-based care organizations to improve provider efficiencies and promote a better quality of life for the people they serve. The transaction includes MatrixCare and related software offerings historically sold under the MatrixCare brand, including Healthcare First, Citus, and home health and hospice solutions.
Stock Futures Mixed as Doximity Soars 83.93%
Stock futures were mixed following a mostly lower regular session as investors continue to digest another round of corporate earnings and await news out of the Middle East.Economic data remains a central focus ahead of Friday's July employment report. Markets remain divided over the Federal Reserve's next policy move, with incoming employment data expected to play an important role in shaping expectations for interest rates over the coming months.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Doximityup 83.93%Atlassianup 32.1%Figsup 24.6%QuinStreetup 23%Cloudflareup 16.9%Twilioup 16.7%Nateraup 15.3%Akamaiup 13%Airbnbup 10.3%Instacartup 9%ALSO HIGHER -DoubleVerifyup 13.2% after Nielsen agreed to acquire the company in an all-cash transaction valued at roughly $2.15BDOWN AFTER EARNINGS -Trade Deskdown 24.5%QuidelOrthodown 21.8%Xponential Fitnessdown 12.9%Cable Onedown 9.5%Maravai Lifesciencesdown 8.8%ResMeddown 5.9%10x Genomicsdown 4.7%Dropboxdown 4.1%Post Holdingsdown 3%
ResMed Increases Quarterly Dividend by 10% to 66 Cents
ResMed increases quarterly dividend 10% to 66c per quarter
Resmed Reports Q4 Revenue of $1.46B
Reports Q4 revenue $1.46B, consensus $1.46B. "We closed fiscal year 2026 with strong fourth quarter results, reflecting continued momentum of our global business, sustained demand for our market-leading products, and disciplined execution of our strategy," said Resmed's Chairman and CEO, Mick Farrell.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.